Global Study on Durvalumab and Domvanalimab After Chemoradiation for Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria

• Must be 18 years or older.
• Have a confirmed diagnosis of non-small cell lung cancer (NSCLC) and have received chemoradiation for locally advanced, unresectable Stage III disease.
• Provide a tumor tissue sample taken before chemoradiation treatment.
• Tumor must have a PD-L1 status of 1% or higher.
• Must not have specific genetic mutations (EGFR and ALK wild-type).
• Cancer must not have worsened after receiving platinum-based chemoradiation.
• Must have completed at least 2 cycles of platinum-based chemotherapy with radiation.
• Must have received a specific dose of radiation (54 Gy to 66 Gy) during treatment.
• Have a WHO performance status of 0 or 1, indicating full activity or some restriction in strenuous activities.
• Have adequate organ and bone marrow function.

Exclusion Criteria

• Have a history of another primary cancer, except for certain types that have been treated and are not active.
• Have a mix of small cell and non-small cell lung cancer.
• Received a different sequence of chemoradiation therapy for Stage III NSCLC.
• Cancer has worsened during platinum-based chemoradiation.
• Have unresolved side effects from previous treatment, except for hair loss.
• Have had significant lung inflammation (pneumonitis) from previous treatment.
• Have certain lung conditions like pulmonary fibrosis or active pneumonia.
• Have active or past autoimmune or inflammatory disorders, with some exceptions.
• Have an active Epstein-Barr virus (EBV) infection.
• Have used immunosuppressive medication within 14 days before starting durvalumab.